Solid Tumor Antigens

Cat. No.

AT0418

CAS No.

2145109-70-0

Praluzatamab

Praluzatamab is a monoclonal antibody specifically designed to target the activated leukocyte cell adhesion molecule (ALCAM), also known as CD116. This antibody has been engineered to facilitate the development of antibody-drug conjugates, such as Praluzatamab ravtansine, enhancing its utility in targeted cancer therapy. Praluzatamab is primarily utilized in oncological research, where it serves as a critical tool in the investigation of cancer pathogenesis and the development of novel therapeutic strategies.

Cat. No.

AT0442

CAS No.

1453084-36-0

Mirvetuximab

Synonyms: M9346A

Mirvetuximab (M9346A) is a monoclonal antibody targeting FOLR1 (folate receptor 1), specifically designed to bind to folate receptor alpha (FRα). This antibody serves as the crucial component of the antibody-drug conjugate (ADC) Mirvetuximab soravtansine, which is utilized in the investigation of ovarian and other FRα-positive cancers. Mirvetuximab soravtansine's mechanism focuses on delivering cytotoxic agents directly to cancer cells expressing FRα, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is essential for research aimed at developing targeted therapies for FRα-expressing tumors.

Cat. No.

AT0450

ALT-836 (TNX-832)

Synonyms: TNX-832

ALT-836 is a recombinant chimeric monoclonal antibody of the IgG4κ subclass that specifically targets human tissue factor (TF) and the TF-FVIIa complex. By binding to these entities, ALT-836 effectively prevents the association and subsequent activation of Factor X (FX), thereby inhibiting the generation of thrombin. This mechanism plays a crucial role in modulating thrombotic processes, making ALT-836 an essential tool for research in coagulation and cardiovascular disorders.

Cat. No.

AT0457

CAS No.

845816-02-6

Lexatumumab

Synonyms: HGS-ETR 2; ETR2-ST01

Lexatumumab (HGS-ETR 2) is a human monoclonal antibody of the IgG4κ subtype that functions as an agonist to TRAIL receptor 2 (TRAIL-R2, also known as DR5 or APO-2). This antibody is specifically designed to induce apoptosis in cells exhibiting malignant mesothelioma characteristics. It is primarily utilized in research focused on understanding and treating malignant pleural mesothelioma (MPM), offering significant value in studies aimed at exploring targeted cancer therapies.

Cat. No.

AT0465

CAS No.

2657613-60-8

Nezastomig

Synonyms: REGN-5678

Nezastomig is a human IgG4 κ monoclonal antibody targeting FOLH1/CD28. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for specificity to FOLH1/CD28, making it suitable for a range of research applications investigating the role of this target in various biological processes.

Cat. No.

AT0471

Anti-Mesothelin Antibody

The Anti-Mesothelin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets mesothelin, a protein frequently overexpressed in various forms of cancer, including mesothelioma and ovarian carcinoma. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a predicted molecular weight of 150 kDa. For isotype control purposes, reference is made to the Human IgG1 kappa, Isotype Control. This antibody serves as a valuable tool for research focused on cancer biology and the therapeutic targeting of mesothelin-positive tumors.

Cat. No.

AT0476

CAS No.

156586-89-9

Edrecolomab

Synonyms: Panorex; CO17-1A

Edrecolomab (Panorex) is a murine monoclonal antibody that targets the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and various carcinomas. This antibody exhibits anti-tumor activity, making it particularly useful in the study of colorectal carcinoma.

Cat. No.

AT0478

CAS No.

1188277-05-5

Flanvotumab

Synonyms: IMC-20D7S

Flanvotumab (IMC-20D7S) is a human monoclonal antibody designed to specifically target tyrosinase-related protein 1 (TYRP1), which is predominantly expressed in melanocytes and melanoma cells. This antibody mediates its effects through the mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC), engaging the body's natural killer cells to destroy tumor cells. Flanvotumab demonstrates significant anti-tumor activity and is well-tolerated, making it a valuable tool for research in melanoma therapeutics.

Cat. No.

AT0490

CAS No.

3018936-99-4

Ixotatug

Ixotatug is a monoclonal antibody designed to selectively target human Claudin-6 (CLDN6), a tight junction protein frequently overexpressed in various tumor types. By binding to CLDN6, Ixotatug disrupts critical signaling pathways within tumor cells, thereby exerting potent antitumor effects. This antibody is particularly valuable for research focused on the pathophysiology and therapeutic targeting of CLDN6-associated cancers.

Cat. No.

AT0491

Anti-pan-Glypican Antibody (HS20)

The Anti-pan-Glypican Antibody (HS20) is a human monoclonal antibody of the IgG1, κ subclass, specifically designed to target human pan-Glypican. For accurate isotype control in experimental setups, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is suitable for a range of research applications, providing specificity and reliability in targeting the pan-Glypican, which is implicated in various cellular processes and disease states.

Cat. No.

AT0495

CAS No.

1412892-09-1

Naptumomab

Naptumomab is a fusion protein incorporating a tumor-targeting superantigen (TTS), designed to enhance the immune system's ability to detect and eliminate tumor cells. This biologic is particularly utilized in research focused on refractory solid tumors, including renal cell carcinoma, providing a valuable tool for investigations into novel cancer immunotherapies.

Cat. No.

AT0501

CAS No.

2883118-92-9

Precemtabart

Precemtabart is a human monoclonal antibody of the IgG1κ subtype that specifically targets CEACAM5. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0506

CAS No.

2349294-95-5

Tusamitamab

Tusamitamab is an IgG1 monoclonal antibody specifically designed to target CEACAM5, a cell surface glycoprotein implicated in various cellular processes and tumor progression. This antibody serves as a foundational component in the synthesis of the antibody-drug conjugate (ADC) Tusamitamab ravtansine (SAR408701), highlighting its utility in targeted cancer therapy research.

Cat. No.

AT0507

CAS No.

339986-90-2

Tucotuzumab

Synonyms: Anti-EPCAM Recombinant Antibody; huKS-IL2

Tucotuzumab is a recombinant IgG1 monoclonal antibody that specifically targets the human epithelial cell adhesion molecule (EpCAM). This antibody is engineered to conjugate two molecules of interleukin-2 (IL-2), enhancing its therapeutic potential. Tucotuzumab acts both as an immunosuppressant and an anti-tumor agent, making it a valuable tool for research in cancer immunotherapy and the study of epithelial cell biology.

Cat. No.

AT0509

Luveltamab

Luveltamab is a human IgG1 κ monoclonal antibody targeting the folate receptor alpha (FOLR1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0512

CAS No.

2764774-90-3

Sigvotatug

Sigvotatug is a human IgG1 κ monoclonal antibody targeting the integrin subunit beta 6 (ITGB6). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0513

CAS No.

1471985-92-8

Vandortuzumab

Vandortuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target STEAP1. This antibody comprises a human IgG1 type heavy chain and a human kappa type light chain, resulting in a predicted molecular weight of 148.74 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT0519

Anti-F3/Factor III/Tissue Factor/CD142 Antibody

The Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the F3 protein, also known as Factor III, Tissue Factor, or CD142, which plays a critical role in the initiation of blood coagulation. The antibody is comprised of a human IgG4 subclass heavy chain with an SP variant and a human kappa light chain. It exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa. This product is essential for research in hematology, particularly in studies involving coagulation pathways and cardiovascular disease mechanisms.

Cat. No.

AT0522

Anti-CD326/EpCAM Antibody (Ber-EP4)

The Anti-CD326/EpCAM Antibody (Ber-EP4) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CD326, also known as Epithelial Cell Adhesion Molecule (EpCAM). This antibody has been engineered for high specificity and affinity toward the EpCAM antigen, a cell surface protein predominantly expressed in epithelial tissues and associated with cell signaling, migration, proliferation, and differentiation. It is commonly utilized in research focusing on cancer biology, particularly in studies involving carcinomas where EpCAM is often overexpressed. For accurate isotype control in experimental assays, the use of Mouse IgG1 kappa Isotype Control is recommended to ensure specificity and consistency in results.

Cat. No.

AT0523

CAS No.

1622305-37-6

Cergutuzumab

Cergutuzumab is a fully human monoclonal antibody of the IgG1 isotype, specifically designed to target CEACAM5, a cell surface glycoprotein implicated in various cellular processes including cell adhesion and signaling. The recommended isotype control for experiments involving Cergutuzumab is Human IgG1 kappa, serving as a critical component for assessing the specificity and background activity of the antibody in various assays.

Cat. No.

AT0525

CAS No.

1412891-40-7

Tenatumomab

Synonyms: ST2146

Tenatumomab (ST2146) is a murine monoclonal antibody developed to target tenascin-C, a large extracellular glycoprotein frequently overexpressed in various cancers. This antibody has demonstrated utility in advanced diagnostic and therapeutic techniques, including Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT). Through PAGRIT, as well as direct labeling with 131-Iodine, tenatumomab facilitates the precise delivery of radionuclides to tumor sites, enhancing the specificity and efficacy of cancer imaging and treatment modalities.

Cat. No.

AT0561

Anti-PSMA Antibody

Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody specifically targeting PSMA (Prostate-Specific Membrane Antigen). This antibody serves as the antigen-binding component of the antibody-drug conjugate (ADC) molecule, ARX517. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT0562

Anti-GPC2/Glypican 2 Antibody

Cat. No.

AT0571

FZ-A038

FZ-A038 is a humanized monoclonal antibody that specifically targets delta-like ligand 3 (DLL3). This antibody serves as a foundational component for the synthesis of the DLL3-targeted antibody-drug conjugate (ADC), FZ-AD005, offering potential applications in therapeutic development.

Cat. No.

AT0578

CAS No.

3023285-05-1

Garetatug

Garetatug is a humanized monoclonal antibody designed to target and bind specifically to human Claudin-18 (CLDN18), a tight junction protein. By binding to CLDN18, Garetatug disrupts critical cell signaling pathways, thereby exerting antitumor effects. This antibody is utilized primarily in research focused on the mechanisms of tumor progression and therapeutic intervention.